Perampanel |
| |
Authors: | YU Peng WANG Yan-li YANG Xin |
| |
Affiliation: | 1.Center of Drug Informatics,Tianjin Institute of Pharmaceutical Research,Tianjin 300193,China 2.Tianjin Institute of Pharmaceutical Research Pharmaceutical Responsible Co.,Ltd.,Tianjin 300193,China |
| |
Abstract: | The AMPA receptor is widely present in almost all excitatory neuronal synapses. It is believed to play a role in a large number of central nervous system diseases with different underlying pathophysiology, including neurodegenerative disorders, movement disorders, pain and psychiatric disorders. Eisai that it will submit Marketing Authorization Applications in the United States and the European Union for the investigational compound Perampanel (E2007) based on the results of three Phase III pivotal studies. Perampanel is a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered and being developed by Eisai for adjunctive treatment of refractory partial seizures in patients with epilepsy. |
| |
Keywords: | Perampanel AMPA glutamate receptor antagonists antiepileptic clinic study |
本文献已被 CNKI 等数据库收录! |
| 点击此处可从《现代药物与临床》浏览原始摘要信息 |
|
点击此处可从《现代药物与临床》下载全文 |
|